ARTISTRY-1 trial showed BIC/LEN is effective in maintaining viral suppression in HIV patients previously on complex ART regimens. BIC/LEN offers a single-tablet alternative for patients with drug-drug ...
– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...
Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results